Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
3.2500-0.1500 (-4.41%)
At close: 04:00PM EST
3.3000 +0.05 (+1.54%)
After hours: 06:14PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
Previous Close3.4000
Open3.4300
Bid3.2800 x 900
Ask3.3800 x 1000
Day's Range3.1700 - 3.4300
52 Week Range1.7700 - 7.4000
Volume183,360
Avg. Volume295,937
Market Cap66.912M
Beta (5Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-2.2270
Earnings DateMar 29, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SLS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SELLAS Life Sciences Group, Inc
    Analyst Report: Johnson & JohnsonJohnson & Johnson is a diversified healthcare company that develops, manufactures and markets products in three primary lines of business: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Products.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program

    Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University of Alabama Participating Site Webcast to be held on Tuesday, January 31, 2023, at 8:30 a.m. EST NEW YORK, Jan. 19, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, will hos

  • GlobeNewswire

    SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs

    Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug ApprovalsNEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs

  • Benzinga

    SELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patients

    SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from its ongoing dose-escalating Phase 1 study of GFH009 in patients with relapsed and/or refractory (r/r) hematologic malignancies. One patient treated with GFH009 in the 30 mg once-per-week cohort achieved a confirmed complete response (CR), which is the first CR reported in acute myeloid leukemia (AML) with any CDK9 inhibitor monotherapy. No minimal residual disease (MRD) was detected in this CR patient, and full neutrophil, plate

Advertisement
Advertisement